DXR: יחס שווי שוק להכנסות Daxor Corp

Daxor Corporation is developing ultra-precise BVA-100 systems and is preparing to release new analyzers. Capitalization is based on the sale of devices and consumables for heart failure therapy. Monitoring the company's P/S ratio clearly demonstrates the market valuation of revenue, where the 331.90 mark characterizes this parameter. Business stability is ensured by patents for blood measurements and strict FDA oversight.

Daxor Corporation (DXR) is developing a high-tech intensive care segment through the implementation of the BVA-100 system. Analyzing the price-to-sales ratio allows for an assessment of market capitalization relative to the issuer's actual cash inflows. This coefficient compares the market price of shares with actual sales volume, separating fundamental growth from speculative overheating. Rational use of this metric protects investors from overvalued assets during periods of hype-driven demand.